d.pro-c.me Open in urlscan Pro
2606:4700::6812:1ae8  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS CONTENT WAS DESIGNED FOR
PORTRAIT ORIENTATION ONLY.



1.0 Credit(s)


HARNESSING THE FULL POTENTIAL OF FRONTLINE IMMUNOTHERAPY IN ADVANCED NSCLC:
PROCEEDINGS FROM A CLINICAL OLYMPICS℠

Please complete and tap PROCEED at the end to submit and continue.


QUESTION 1 OF 8

How many patients with advanced non-small cell lung cancer (NSCLC) do you see in
your practice each week?

 * 0
   
   
 * 1 to 10
   
   
 * 11 to 20
   
   
 * 21 to 30
   
   
 * >30
   
   
 * I do not directly provide care
   
   
   


QUESTION 2 OF 8

How confident are you in your ability to manage immune-related adverse events
(irAEs) in patients receiving frontline immune checkpoint inhibitor (ICI)
therapy?

 * Not at all confident
   
   
 * Somewhat confident
   
   
 * Moderately confident
   
   
 * Very confident
   
   
 * Completely confident
   
   
   


QUESTION 3 OF 8

How often do you consider single-agent immunotherapy for the frontline treatment
of metastatic NSCLC with high PD-L1 expression?

 * Never
   
   
 * Rarely
   
   
 * Sometimes
   
   
 * Often
   
   
 * Always
   
   
   


QUESTION 4 OF 8

According to guidelines, which of these biomarker testing strategies BEST
optimizes frontline treatment selection for stage IV lung adenocarcinoma?

 * Stepwise testing limited to EGFR, ALK, ROS1, and PD-L1
   
   
 * PD-L1 testing first, then molecular testing if levels are <50%
   
   
 * EGFR, ALK, and ROS1 panel, then order PD-L1 if negative
   
   
 * Next-generation sequencing with simultaneous PD-L1 testing
   
   
   


QUESTION 5 OF 8

David presents with left hip pain and multiple pelvic lesions from a primary
lung tumor. He undergoes right iliac bone biopsy, which shows metastatic
adenocarcinoma. Biomarker testing reveals an EGFR L858R mutation and PD-L1
expression level of 20%. Which of the following treatments is most
appropriate in the frontline setting?

 * Immunotherapy
   
   
 * Targeted therapy
   
   
 * Chemotherapy
   
   
 * Chemoradiation
   
   
   


QUESTION 6 OF 8

Which of the following best captures metastatic NSCLC subtypes most likely to
benefit from frontline ICI monotherapy in the absence of targetable molecular
alterations?

 * Nonsquamous NSCLC with PD-L1 ≥1%
   
   
 * NSCLC of any histology with PD-L1 ≥1%
   
   
 * Squamous NSCLC with PD-L1 ≥50%
   
   
 * NSCLC of any histology with PD-L1 ≥50%
   
   
   


QUESTION 7 OF 8

John is newly diagnosed with stage IV squamous NSCLC. Biomarker testing reveals
no targetable molecular alterations and PD-L1 expression in 85% of cells. Which
of the following represents all approved options for frontline ICI monotherapy?

 * Pembrolizumab monotherapy
   
   
 * Pembrolizumab or atezolizumab monotherapy
   
   
 * Pembrolizumab, atezolizumab, or cemiplimab monotherapy
   
   
 * Pembrolizumab, atezolizumab, cemiplimab, or nivolumab monotherapy
   
   
   


QUESTION 8 OF 8

Sabine, a fit patient with good performance status and no comorbidities, is
receiving ICI monotherapy for advanced NSCLC. Liver function tests (LFTs)
indicate a Grade 2 liver toxicity, and she is started on a course of prednisone.
Which follow-up tests are recommended during corticosteroid initiation?

 * Abdominal CT
   
   
 * LFTs every week
   
   
 * Liver biopsy
   
   
 * LFTs every day
   
   
   

PROCEED


PROGRESS

PRE-TEST



MOLECULAR CLASSIFICATION: A GAME CHANGER



QUESTION #1



THE CRITICAL IMPORTANCE OF BIOMARKER TESTING



QUESTION #2



NAVIGATING THE NUANCES OF IMMUNOTHERAPY SELECTION



QUESTION #3



EXPERT GUIDANCE ON MANAGING IMMUNE-RELATED ADVERSE EVENTS



POST-TEST




CME/CNE INFORMATION

SLIDES

FACULTY BIOS

SHARE THIS PRESENTATION

MORE FROM RMEI

PROVIDED BY

RMEI Medical Education, LLC

STATEMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from
Regeneron Pharmaceuticals, Inc and Sanofi.

FACULTY

Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States

Jared M. Weiss, MD, has relevant financial relationships with AstraZeneca,
Boehringer Ingelheim, Eli Lilly, G1 Therapeutics, Merck, Mirati, Sumitomo
Dainippon Pharma (Researcher); AbbVie, AstraZeneca, Azira, Eli Lilly, EMD
Serono, G1 Therapeutics, Genentech, Genmab, Jazz Pharmaceuticals, Jounce
Therapeutics, Nanobiotix, Pfizer, Regeneron, Sumitomo Dainippon Pharma
(Consultant); Achilles, En Fuego Therapeutics, Lyell, Nuvalent, Vesselon
(Stock/Stockholder).

Prof. MUDr. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic

Prof. MUDr. Aleš Ryška, MD, PhD, has relevant financial relationships with
Amgen, Elphogene, Lilly, MSD, Roche (Advisor); Amgen, Bristol-Myers Squibb,
Gilead, MSD, Roche (Speaker/Speaker’s Bureau); Roche, Sanofi (Other: Travel
Support).

Mihaela Aldea, MD, PhD
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France

Mihaela Aldea, MD, PhD, has a relevant financial relationship with Sandoz
(Other: Travel/Expenses).

Terms of Use | Privacy Policy | Feedback

This site uses cookies.Learn More.
×